TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06766578

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Therapy(5×3Gy radiotherapy)
Description: Radiotherapy: 5×3Gy. The preoperative radiotherapy target was outlined by radiotherapy physicians according to the NCCN Guidelines for Gastric/esophagogastric Junction Tumor 2024 edition and the surgeon's opinions. The first and third cycles were 5×3Gy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Therapy(tirelizumab, oxaliplatin, S-1)
Description: The first and third cycles are 5×3Gy radiotherapy D1 to 5, intravenous administration for tirelizumab 200 mg D6, intravenous administration for oxaliplatin 130 mg/m2 D6, and oral administration twice a day for S-1 40 mg/m2 D6 to 19. The second and fourth cycles are intravenous administration for tirelizumab 200 mg D1, intravenous administration for oxaliplatin 130 mg/m2 D1, and oral administration twice a day for S-1 40 mg/m2 D1 to 14. Every treatment cycle is spaced 1 week apart.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Description: Surgical treatment is completed within 3-5 weeks after the end of neoadjuvant therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy(SOX chemotherapy)
Description: Postoperative adjuvant therapy is 4 cycles of SOX chemotherapy.
Study: NCT06765772

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block
Description: the patient will recieve ultrasound guided erector spinae plane blockbe. A 20-gauge needle will be placed between the erector spinae muscle and the thoracic transverse processes at the level of T10 using an 'in plane' technique, 20 ml of (0.25% bupivacaine and 1% xylocaine) will be injected on each side.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block
Description: the patient will recieve ultrasound guided erector spinae plane blockbe. A 20-gauge needle will be placed between the erector spinae muscle and the thoracic transverse processes at the level of T10 using an 'in plane' technique, 20 ml of (0.25% bupivacaine and 1% xylocaine) will be injected on each side.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rectus sheath block
Description: the patient will recieve ultrasound guided rectus sheath block. An 18-gauge needle will be introduced- in plane- just below the costal margin at an angle of approximately 45 degrees to the skin between the rectus abdominis muscle and posterior rectus sheath. 10 ml of (0.25% bupivacaine and 1% xylocaine) will be injected on each side.
Study: NCT06763861

Intervention type: OTHER
Intervention: Biopsy
Description: Biopsies from EAS

Intervention type: OTHER
Intervention: Biopsy
Description: Biopsies from EAS
Study: NCT06766526

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy
Description: An eight week ICBT treatment. The treatment is modular and tailored to the problem profile of the participant. One module will be administered every week during the treatment phase.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-directive support
Description: Participants randomized to this condition will receive weekly support and contact with a therapist via the treatment platform. They will not have access to the treatment modules during the treatment phase.
Study: NCT06765174

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Suction Drain placement (Example: Q-vac)
Description: After thyroid surgery we pust drain at bed of surgery to monitor post operative bleeding.
Study: NCT06766630

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silk fibroin surgical mesh
Description: This product is a mesh patch made of mulberry silk by warp knitting and degumming. The main component is fibroin protein
Study: NCT06764251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab + SOX
Description: tislelizumab combined with SOX
Study: NCT06768853

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lymph node dissection based on the guidelines
Description: During surgery, mediastinal lymph nodes will be dissected based on the NCCN guidelines (2023) .

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymph node dissection based on the model
Description: During surgery, lymph nodes will be dissected based on the predicted lymph node status by the model.
Study: NCT04965090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib
Description: Lazertinib 240 mg orally once daily and take this continuously, starting C1D1. For patients who weigh \<80 kg, on C1D1, patients will receive amivantamab 350 mg IV, with 700 mg given on C1D2.
Study: NCT06646575

Intervention type: OTHER
Intervention: Qualitative data, no intervention
Description: This is a qualitative study
Study: NCT05960864

Intervention type: DRUG
Intervention: Celecoxib
Description: If we find any behavior that affects the safety of patients in the experiment, we will stop

Intervention type: DRUG
Intervention: Celecoxib
Description: If we find any behavior that affects the safety of patients in the experiment, we will stop
Study: NCT04104022

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged Exposure Therapy
Description: Within the general population, prolonged exposure therapy (PET) is a widely-used, empirically-supported and manualized therapy that is regarded as a first-line cognitive-behavioral treatment for posttraumatic stress disorder (PTSD). PET is designed to disrupt the cycle of anxiety and avoidance that characterizes PTSD via sustained imaginal and in-vivo exposure exercises that deliberately and systematically expose patients to painful memories and current, real-life trauma reminders that were previously avoided, yet not inherently harmful. Overall, PET has well-documented efficacy for reducing PTSD symptom severity in both civilian and veteran populations. PET is effective for reducing PTSD symptoms regardless of whether it is delivered remotely or face-to-face. Recent data also suggest that PET can improve PTSD symptoms without exacerbating substance use or craving among patients with substance use disorders when PET and substance use disorder treatment are delivered concurrently.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure Therapy
Description: Within the general population, prolonged exposure therapy (PET) is a widely-used, empirically-supported and manualized therapy that is regarded as a first-line cognitive-behavioral treatment for posttraumatic stress disorder (PTSD). PET is designed to disrupt the cycle of anxiety and avoidance that characterizes PTSD via sustained imaginal and in-vivo exposure exercises that deliberately and systematically expose patients to painful memories and current, real-life trauma reminders that were previously avoided, yet not inherently harmful. Overall, PET has well-documented efficacy for reducing PTSD symptom severity in both civilian and veteran populations. PET is effective for reducing PTSD symptoms regardless of whether it is delivered remotely or face-to-face. Recent data also suggest that PET can improve PTSD symptoms without exacerbating substance use or craving among patients with substance use disorders when PET and substance use disorder treatment are delivered concurrently.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attendance-based monetary incentives
Description: Participants will earn vouchers that have monetary value for attending scheduled PET appointments. Each consecutive attended session will increase the voucher amount so that each consecutively attended appointment is worth an incrementally higher dollar amount. To support completion of the full 12-week PET protocol, we will also incorporate additional strategically-placed bonuses into the reinforcement schedule with the goal of maximizing the percentage of subjects who complete the full 12-session protocol. First, to support consistent (vs. sporadic) attendance, participants will receive a bonus for every two consecutive sessions attended. Second, to support completion of the full PET protocol, participants will receive an additional bonus upon completion of Session 12.
Study: NCT06162013

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nicotinamide Riboside
Description: Nicotinamide Riboside 3000mg/day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo. Identical in taste and appearance as the intervention.
Study: NCT06096545

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Axillary sentinal lymph node biopsy
Description: For SLNB evaluation, multiple sections of the excised lymph node were stained with hematoxylin and eosin (H\&E) at a thickness greater than 2 mm. Lymph nodes with metastasis greater than 2 mm were defined as positive SLNB. Macroscopic metastasis was considered positive in the evaluation for the axilla, while benign histological characteristics were considered negative. The presence of micrometastasis and isolated tumor cells was also noted. The size and diameter of the metastatic lymph node were considered in the evaluation.~SLNB technique using isosulfan blue dye was performed for axillary evaluation, and all patients had the clipped lymph node excised under ultrasound guidance with a guide wire placed preoperatively.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Axillary sentinal lymph node biopsy
Description: For SLNB evaluation, multiple sections of the excised lymph node were stained with hematoxylin and eosin (H\&E) at a thickness greater than 2 mm. Lymph nodes with metastasis greater than 2 mm were defined as positive SLNB. Macroscopic metastasis was considered positive in the evaluation for the axilla, while benign histological characteristics were considered negative. The presence of micrometastasis and isolated tumor cells was also noted. The size and diameter of the metastatic lymph node were considered in the evaluation.~SLNB technique using isosulfan blue dye was performed for axillary evaluation, and all patients had the clipped lymph node excised under ultrasound guidance with a guide wire placed preoperatively.
Study: NCT06417229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986365
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986365
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986365
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986365
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986365
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986365
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986365
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986365
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986365
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986365
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986365
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: Specified dose on specified days
Study: NCT05621668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: attIL2-T cells
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: attIL2-T cells
Description: Given by IV (vein)
Study: NCT05044325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3884464
Description: GSK3884464 will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3884464
Description: GSK3884464 will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3884464
Description: GSK3884464 will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3884464
Description: GSK3884464 will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3884464
Description: GSK3884464 will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3884464
Description: GSK3884464 will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3884464
Description: GSK3884464 will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3884464
Description: GSK3884464 will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3884464
Description: GSK3884464 will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match GSK3884464 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match GSK3884464 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match GSK3884464 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match GSK3884464 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match GSK3884464 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match GSK3884464 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match GSK3884464 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match GSK3884464 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match GSK3884464 will be administered.
Study: NCT05256030

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Speed-based relearning training
Description: Spasticity, balance and gait exercises will be started at slow speeds, at muscle level, and in the following sessions, movement speed will be increased in relation to the patient's compliance, and global balance and gait exercises will be performed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurodevelopmental Therapy
Description: Neurodevelopmental Therapy
Study: NCT05731947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revumenib
Description: Revumenib administered orally with or without food. Participants may continue to receive treatment until disease progression or until they experience unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revumenib
Description: Revumenib administered orally with or without food. Participants may continue to receive treatment until disease progression or until they experience unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revumenib
Description: Revumenib administered orally with or without food. Participants may continue to receive treatment until disease progression or until they experience unacceptable toxicity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Either Lonsurf® or Stivarga® administered per the investigator's choice at the respective drug label's dose and schedule. Participants may continue to receive treatment until disease progression or until they experience unacceptable toxicity.
Study: NCT05330130

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Follitropin beta injection 150 IU
Description: Participants commence ovarian stimulation on day 2 or 3 of their menstrual cycle with a daily dosage of 150 IU rec-FSH. The dosage will remain constant throughout the course of the stimulation. From the morning of the 5th stimulation day, GnRH-antagonist will be administered daily to prevent LH-rise. As soon as ≥ 3 follicle of a size of 17mm are seen, 0.3 mg GnRH-Agonist will be administered for final oocyte maturation. During ovarian stimulation, follicle puncture procedures with the aspiration of follicular fluid will be performed at the following time:~* one follicle on the morning of day 5, before the administration of the first GnRH-antagonist~* one follicle of the size of 12 to 14 mm, when at least 2 to 3 follicles have reached a size of 12 to 14 mm~* two follicles (= pre-ovulatory follicle) on the morning of the day of final oocyte maturation.~Oocyte retrieval of all other follicles will be carried out 36 hours after injection of the medication for final oocyte maturation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Follitropin beta injection 300 IU
Description: Participants commence ovarian stimulation on day 2 or 3 of their menstrual cycle with a daily dosage of 300 IU rec-FSH. The dosage will remain constant throughout the course of the stimulation. From the morning of the 5th stimulation day, GnRH-antagonist will be administered daily to prevent LH-rise. As soon as ≥ 3 follicle of a size of 17mm are seen, 0.3 mg GnRH-Agonist will be administered for final oocyte maturation. During ovarian stimulation, follicle puncture procedures with the aspiration of follicular fluid will be performed at the following time:~* one follicle on the morning of day 5, before the administration of the first GnRH-antagonist~* one follicle of the size of 12 to 14 mm, when at least 2 to 3 follicles have reached a size of 12 to 14 mm~* two follicles (= pre-ovulatory follicle) on the morning of the day of final oocyte maturation.~Oocyte retrieval of all other follicles will be carried out 36 hours after injection of the medication for final oocyte maturation.
Study: NCT05526963

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication plan review
Description: Intervention group patients will receive a revised medication plan by external pharmacologist based on the the STOPP/START criteria. The revised medication plan will be provided to the family physician who then will provide it to the patient. The revision comes along with evidence based information for the physician to prevent possible uncertainties by the physicians.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence support
Description: Intervention group patients will receive a study nurse administered adherence support measure based on telephone-based motivational interviewing. The measure includes information on possible consequences of inadherence and signs of adverse drug reactions that is comprehensible for lay persons.
Study: NCT04804358

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exposition Test
Description: During this test (7 minutes) participants will be exposed to photos evoking positive or negative emotions (anger, disgust, sadness and fear) interspersed with emotionally neutral photos.~The test sequence is composed of 3 blocks as follows:~* 12 photos evoking positive emotions (2 min)~* Pause of 30 seconds (white screen)~* 12 photos presenting a neutral emotional valence (2 min)~* Pause of 30 seconds (white screen)~* 12 photos evoking negative emotions (2min)~In each block, photos will be selected and presented to the participant in a randomized and sequential manner. In total, 30 photos will be presented in 7 minutes to each participant (10 seconds per photo).~The participant must be at rest in front of the computer screen during these 7 minutes with optimal visibility. The photos will be presented sequentially using software (E-Prime or Visual Basic 6.0). During this exposure test, a heart rate recording will be made using a BIOPAC MP160 recording system.
Study: NCT05328297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-55308942
Description: JNJ-55308942 capsules will be administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules will be administered orally.
Study: NCT06257082

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Online Survey
Description: Participants must self-identify as Latinx adults and complete a brief online survey adapted from validated survey instruments for eye health literacy and trust in healthcare (CADEES and T-HCT scale) both before and after viewing the video-based, patient education intervention to obtain a pre to post-comparison of any differences in their responses.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Online Survey
Description: Participants must self-identify as Latinx adults and complete a brief online survey adapted from validated survey instruments for eye health literacy and trust in healthcare (CADEES and T-HCT scale) both before and after viewing the video-based, patient education intervention to obtain a pre to post-comparison of any differences in their responses.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Online Survey
Description: Participants must self-identify as Latinx adults and complete a brief online survey adapted from validated survey instruments for eye health literacy and trust in healthcare (CADEES and T-HCT scale) both before and after viewing the video-based, patient education intervention to obtain a pre to post-comparison of any differences in their responses.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Online Survey
Description: Participants must self-identify as Latinx adults and complete a brief online survey adapted from validated survey instruments for eye health literacy and trust in healthcare (CADEES and T-HCT scale) both before and after viewing the video-based, patient education intervention to obtain a pre to post-comparison of any differences in their responses.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Online Survey
Description: Participants must self-identify as Latinx adults and complete a brief online survey adapted from validated survey instruments for eye health literacy and trust in healthcare (CADEES and T-HCT scale) both before and after viewing the video-based, patient education intervention to obtain a pre to post-comparison of any differences in their responses.
Study: NCT01338844

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Myo-inositol

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: D-chito-Inositol
Study: NCT05609552

Intervention type: COMBINATION_PRODUCT
Intervention: 18F-Pretomanid PET/CT
Description: A bolus of less than or equal to 10 mCi (370 MBq) of 18F-pretomanid will be injected into the intravenous line by slow IV push. Immediately after administration of 18F-pretomanid, dynamic PET acquisition will take place.
Study: NCT06244212

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Demonstration of applying triamcinolone cream
Description: Live demonstration of applying 1 fingertip unit of triamcinolone cream

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile App Use
Description: Additional mobile application that provides amount dispensed and adherence data.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Written/verbal instructions only